Earnings
Home›Earnings›Analyst Ratings›Trevi Therapeutics shares jump on clinical data for Ha…
Trevi Therapeutics shares jump on clinical data for Haduvio
Haduvio is tied to a chronic cough market expected to rise from $9.0 billion in 2024 to $14.0 billion to $15.0 billion by 2035.
Trevi Therapeutics shares rose 9.9 percent on Friday to close at $19.07 after management highlighted strong clinical trial results for its oral chronic cough treatment candidate, Haduvio, at a three-day conference in Europe, according to Yahoo Finance.
In presentations, CEO Jennifer Good and Chief Development Officer James Cassella said Haduvio demonstrated a significant reduction in cough frequency in trials for refractory chronic cough or RCC and for idiopathic pulmonary fibrosis or IPF, with the company positioning the program as a potential milestone if it gains approval.
Yahoo Finance also cited Hyfe data showing the total addressable market for chronic cough could reach $14.0 billion to $15.0 billion by 2035, up from $9.0 billion in 2024, implying about 6.0 percent compounded annual growth across the US, the UK, the European Union, and Japan.
The company has not generated commercial revenue from Haduvio yet. Trevi Therapeutics is planning an adaptive design Phase 2b trial for non-IPF ILD-related chronic cough in the second half of 2026, with topline results expected in the second half of 2027, and Yahoo Finance noted that institutional interest has increased, with 40 hedge funds holding positions at the end of the first quarter, up from 35 in the prior quarter.